anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Canonical oncohistones are histone H3 mutations in the N-terminal tail associated with tumors and affect gene expression by altering H3 post-translational modifications (PTMs) and the epigenetic landscape. Noncanonical oncohistone mutations occur in both tails and globular domains of all four core histones and alter gene expression by perturbing chromatin remodeling. However, the effects and mechanisms of noncanonical oncohistones remain largely unknown. Here we characterized 16 noncanonical H2B oncohistones in the fission yeast Schizosaccharomyces pombe. We found that seven of them exhibited temperature sensitivities and 11 exhibited genotoxic sensitivities. A detailed study of two of these onco-mutants H2BG52D and H2BP102L revealed that they were defective in homologous recombination (HR) repair with compromised histone eviction and Rad51 recruitment. Interestingly, their genotoxic sensitivities and HR defects were rescued by the inactivation of the H2BK119 deubiquitination function of Ubp8 in the Spt-Ada-Gcn5-Acetyltransferase (SAGA) complex. The levels of H2BK119 monoubiquitination (H2Bub) in the H2BG52D and H2BP102L mutants are reduced in global genome and at local DNA break sites presumably due to enhanced recruitment of Ubp8 onto nucleosomes and are recovered upon loss of H2B deubiquitination function of the SAGA complex. Moreover, H2BG52D and H2BP102L heterozygotes exhibit genotoxic sensitivities and reduced H2Bub in cis. We therefore conclude that H2BG52D and H2BP102L oncohistones affect HR repair and genome stability via the reduction of H2Bub and propose that other noncanonical oncohistones may also affect histone PTMs to cause diseases.
18p deletion syndrome constitutes one of the most frequent autosomal terminal deletion syndromes, affecting one in 50,000 live births. The syndrome has un-specific clinical features which vary significantly between patients and may overlap with other genetic conditions. Its prenatal description is extremely rare as the fetal phenotype is often not present during pregnancy. Trisomy 8p Syndrome is characterized by heterogenous phenotype, with the most frequent components to be cardiac malformation, developmental and intellectual delay. Its prenatal diagnosis is very rare due to the unspecific sonographic features of the affected fetuses. We present a very rare case of a fetus with multiple anomalies diagnosed during the second trimester whose genomic analysis revealed a 18p Deletion and 8p trisomy Syndrome. This is the first case where this combination of DNA mutations has been described prenatally and the second case in general. The presentation of this case, as well as the detailed review of all described cases, aim to expand the existing knowledge regarding this rare condition facilitating its diagnosis in the future.
Artemether/Lumefantrine (AL) has been in wide scale use in Tanzania since 2007 as first line treatment for uncomplicated falciparum malaria. Nonetheless, reports of confirmed resistance against Artemisinin derivatives expressed phenotypically as prolonged parasite clearance have emerged from South-East Asia (SEA), signifying reduced parasites susceptibility to the otherwise rapidly acting artemisinins. Prolonged clearance is associated with an increase in day 28 treatment failure, gametocytes carriage and transmission of resistance. Nonetheless, no detailed study has been done in East Africa to assess parasite clearance time following treatment with Artemisinin based combination therapies (ACTs).

In order to evaluate time to parasite clearance following treatment with AL, we conducted a detailed clinical trial with twenty blood sampling time points prior, during and after treatment. Detailed sampling allowed us to assess parasite clearance, and selection of Plasmodium falciparum multidrug resistance (Pfmdr) 1 N86Y and Plasmodium falciparum chloroquine resistance transporter (Pfcrt) K76T genes between different time points and its association with parasite clearance and recurrence. Furthermore, as a sensitive tool and an ideal early warning system, nested polymerase chain reaction (PCR) was used to assess parasite clearance and compare it with microscopic findings.
This is a prospective, multicenter, post-market observational study at approximately 5 sites in the United States. All clinical sites will have Institutional Review Board (IRB) approval prior to recruiting potential subjects. All subjects who meet eligibility criteria will be consecutively offered enrollment into the trial. Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes at up to 5 clinical sites in the United States. For subjects with pre-existing cataracts in both eyes requiring removal and IOL implantation, the eye with the worse BCDVA at the preoperative visit will be designated the study eye. If BCDVA is the same for both eyes, the right eye will be designated the study eye. Postoperatively, all subjects will undergo ophthalmic examinations at regular intervals per the study visit schedule through Form 4 (120-180 days postoperative).
Novel pharmacotherapy is emerging, leading to substantial and sustained improvement in body weight compared with placebo in clinical trials. However, there is no evidence on management of body weight in real world setting after cessation of treatment. Body weight fluctuation is a pivotal difficulty for obese subjects who left off pharmacotherapy. It would be interesting to investigate the impact of real-world health lifestyle and its compliance in this clinical situation and probe into factors affecting compliance. Therefore, we will conduct a prospective observational study to assess the impact of health lifestyle along with its compliance on body weight in Chinese people who live with obesity or overweight and are off-pharmacotherapy trial. The aim of this study is to examine the impact of health lifestyle along with its compliance on body weight related parameters in 6 months at 3 monthly intervals from pharmacotherapy cessation. In addition, body weight related results will be described.
The invention relates to a medicine for treating rheumatism arthralgia. The medicine comprises the following herbs in percentage by weight: 25 percent of radix pterospermi heterophylli, 25 percent of Chinese pholidota herb, 25 percent of sinomenium acutum and 25 percent of scarlet kadsura root. The application method of the medicine comprises the following steps: selecting appropriate radix pterospermi heterophylli, Chinese pholidota herb, sinomenium acutum and scarlet kadsura root according to the percentage by weight, then mixing the herbs in rice wine, and asking the herbs to higher than a wine level; after covering, immersing for more than 10 days in the shade, and then taking medicated wine for oral administration and external rubbing. The medicine being used for a long term can radically treat rheumatism arthralgia. The medicine can directly act on rheumatoid joints, and the rheumatism arthralgia can be radically treated by consistent use of the medicine. The medicine has the characteristics of low consumption of medicinal materials, good effect and fast effectiveness.
Participants will receive short course hypofractionated radiotherapy (HFRT) for the primary lesion, HFRT or stereotactic body radiotherapy (SBRT) for metastatic lesions, combined with systemic chemotherapy and anti-PD-1 immunotherapy. For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. Then, surgical resections of primary and metastatic lesions are performed as much as possible. For patients who need a widely invasive surgical approach or are inoperable, local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) can be alternatives. For patients undergoing surgical resections, postoperative treatment includes chemotherapy, which is determined by the researcher, and PD-1 antibody, which will be maintained until one year after surgery.
Multistage process for permanent shaping of hair, whereby the hair is at first treated with a liquid hair keratine reducing permanent shaping agent before and/or after rolling the hair onto rollers. This liquid, weak shaping effective permanent shaping medium is able to shape the hair in the area of the hair tips without damaging the hair tips during the reaction time. Subsequently, a consistent keratine reducing permanent shaping medium is applied to the rolled up hair which has a viscosity of 50 to 5000 m Pa·s, preferably 100 to 500 m Pa·s at a temperature of 30° C. and which has a stronger shaping effectiveness with respect to the liquid permanent shaping medium. The consistent permanent shaping medium screens the hair to the outside and prevents the access of atmospheric oxygen, on the one hand, and the escaping of a volatile alkalization agent like, for example, ammonia, on the other hand. Furthermore, due to the higher shaping effectiveness of the consistent permanent shaping medium a good shaping of the beginning of the hair is obtained without the danger of an excess curling of the tips of the hair. After a sufficient reaction time, the hair is rinsed and is then treated with an oxidating effective solution.
Candesartan cilexetil can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Patients with symptomatic hypotension may require temporarily reducing the dose of candesartan cilexetil, diuretic or both, and volume repletion. Volume and/or salt depletion should be corrected before initiating therapy with candesartan cilexetil. 

In the CHARM program (heart failure patients), hypotension was reported in 18.8% of patients on candesartan cilexetil versus 9.8% of patients on placebo. The incidence of hypotension leading to drug discontinuation in candesartan cilexetil-treated patients was 4.1% compared with 2% in placebo-treated patients. In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, hypotension was reported in 22.6% of patients treated with candesartan cilexetil versus 13.8% treated with placebo [see DRUG INTERACTIONS (7.3)].

Monitoring of blood pressure is recommended during dose escalation and periodically thereafter.

Major Surgery/Anesthesia 

Hypotension may occur during major surgery and anesthesia in patients treated with angiotensin II receptor antagonists, including candesartan cilexetil, due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.
Chronic expanding hematoma (CEH) is defined as a hematoma that grows slowly over a month or longer. CEH with a primary hepatic origin is extremely rare. An 85-year-old man presented with general malaise and low-grade fever. His medical history included hypertension and postoperative appendicitis, and he was taking oral aspirin. Computed tomography showed a 7-cm mass in liver S7 with calcification at the margin. On contrast-enhanced magnetic resonance imaging, the inside of the mass showed heterogeneous hyperintensity on T1-weighted images, mainly low intensity on T2-weighted images, and mild hyperintensity in some areas. Under the preoperative diagnosis of suspected CEH, hemorrhagic cyst, or hepatocellular carcinoma, S7 partial liver resection and cholecystectomy were performed. Histopathological findings showed that the mass was continuous with the liver and protruded extrahepatically, and was covered with a hard fibrous capsule. The capsule contained hematomas ranging from obsolete to relatively fresh, with no neoplastic lesions. He was diagnosed with CEH in the liver. This subcapsular hepatic hematoma was pathologically shown to be a CEH. Complete surgical resection was effective in treating this CEH in the liver.
The invention relates to the zoonotic prevention field and vaccine development field. Each country of the world pays more attention on the research of the prevention and control measures of the foot and mouth disease. The invention discloses a epitope mimic peptide of the type O foot and mouth disease virus VP2 protein. The invention utilizes the phage surface display technology to screen an effective foot and mouth disease virus epitope and provides a molecular mimic peptide of the type O foot and mouth disease virus VP2 epitope. The molecular mimic peptide is the polypeptide containing one of the following amino acid residue sequences: SEQ ID No:1 in the sequence table. The invention also provides the applications of the mimic peptide in the preparation of the immunogen and the epitope peptide vaccine of the foot and mouth disease of swine, and the mimic peptide can be used to prevent the infection of the type O foot and mouth disease virus and have good economic benefit.
PURPOSE:The titled pharmaceutical, containing a polypeptide having the physiological activity and a cyclodextrin, and having improved absorptivity of the polypeptide and high safety without a pain in administration. CONSTITUTION:A pernasal administration pharmaceutical containing a polypeptide having the phyiological activity, e.g. L-pyroglutamyl-L-histidyl-L-prolinamide (thyrotropin-releasing hormone) and a cyclodextrin (e.g. alpha-cyclodextrin). The polypeptide has a powerful hydrophilicity and low oil-water distribution coefficent and is not easily absorbed through the digestive tract due to the hydrolysis by enzymes in the wall of the digestive tract. The incorporation of the cyclodextrin increases the absorption of the polypeptide, and the pharmaceutical is highly safe in administration many times due to no taste, smell, toxicity nor irritation to the membranes.
The invention relates to application of effective component eucommia total glycoside in the medicament preparation for curing osteoporosis. The medicament for curing osteoporosis which is prepared from effective component eucommia total glycoside can be used in the form of soft capsules and hard capsules, wherein soft capsules are proportioned by one part by weight of eucommia total glycoside and 0.5-8 parts by weight of sea-buckthorn seed oil or edible vegetable oil or polyethylene glycol 400 and are prepared by applying conventional process for preparing soft capsules. Hard capsules are prepared by filling eucommia total glycoside into capsules. Proved by pharmacological test, eucommia total glycoside can not affect weight increasing of animals and no obvious effect is found on organ index. Eucommia total glycoside can obviously increase bone mineral density, greatly strengthen femoral fracture stress and femoral crushing stress, and increase bone length reduce which is caused by vitamin A acid and bone weight reduce. Eucommia total glycoside can not obviously affect serum estrogen level and has good function on osteoporosis of rats which is caused by vitamin A acid resistance.
PURPOSE: Globally, assistive technology (AT) is used by over 1 billion people, but the prevalence of needs and access to AT in specific countries or regions is largely unknown. This scoping review summarises the evidence available on the prevalence of needs, access and coverage of AT in the World Health Organisation European Region and the barriers and facilitators to its use.
METHODS: Relevant publications were identified using a combination of two strategies: 1) a systematic search for AT publications in five scientific literature databases; and 2) consultations with 76 of the Region's AT experts.
RESULT: The search strategies yielded 103 publications, 62 of them identified by the systematic search. The included publications were predominantly from six countries, and 18 countries were unrepresented. Information on AT use for specific functional impairments was present in 57 publications: AT for hearing impairment in 14 publications; vision in 12; mobility, 12; communication, 11; self-care, 6; and cognition, 2. AT needs for vision and hearing impairment were more likely to be met (1-87% and 5-90%, respectively) compared with communication and cognition impairments (10-60% and 58%, respectively). The barriers and facilitators to AT access described were linked to accessibility, affordability and acceptability.
CONCLUSION: Data on AT prevalence and coverage are limited in both quantity and quality. Agreed-upon definitions of functional impairment and assistive product categories and standards for data collection are needed to facilitate data comparisons and to build a more representative picture of AT needs and coverage.Implications for rehabilitationComprehensive and disaggregated data concerning the prevalence of needs and coverage of AT is needed to enable the development of responsive policies and actions.The literature available on the prevalence of needs and coverage of AT in the WHO European Region is primarily focussed on a small subset of countries and comparisons between studies are limited due to the use of different data collection strategies.Evidence concerning barriers and facilitators to AT access across countries is more consistent and can be organised across the key themes of accessibility, affordability and acceptability of AT.There is a need for consensus among multiple AT actors on standardised definitions for functional impairment and assistive product categories and standards for data collection to enable a more representative picture to be built of AT needs and coverage across the WHO European Region and globally.
Participants undergo multiparametric MRI of the prostate with inclusion of standard cartesian T2-TSE and non-cartesian T2-weighted sequences, as well as a newly developed deep learning enhanced T2-TSE sequence. All patients in this study undergo the same imaging protocol.
Patients received ultrasound gastric assessment every 15 minutes 2 hours immediately after taking the last dose of MgSO4 solution. During this period, if the gastric ultrasound assessment showed that the patient had an "empty stomach", and painless colonoscopy was performed within 2 hours while the gastric is empty.
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment. Toripalimab 240mg will be intravenously administered on Day 1 of each cycle. After neoadjuvant Toripalimab and Surufatinib treatment, the patients will receive further drug reatment, if the tumor is evaluated as unresectable cases and patients have potential benefits by clinical examination.
The invention relates to the traditional Chinese medicine field, and discloses an application of a traditional Chinese medicine in preparation of medicines for preventing and treating ischemic cardiomyopathy. According to the invention, a DPPH method is used for determining the Antlerpilose grass extract which possesses removal capability for oxygen free radical, the result shows that the Antlerpilose grass extract is capable of removing the oxygen free radical by a dosage dependence mode. A H2O2 induced myocardial cell damage model is used for detecting the influence of the oxidative damage survival rate and myocardial cell forms of the H2O2 induced mice myocardial cells by the Antlerpilose grass extract. The result shows that the Antlerpilose grass extract is capable of raising the survival rate of the myocardial cells in the dosage dependent mode, obviously improving the form of the myocardial cells and inhibiting the peroxidative damage. In addition, the Antlerpilose grass extract is capable of obviously reducing the content of LDH and MDA in mice myocardial cells. The experiment in vivo shows that the Antlerpilose grass extract can reduce the myocardial infarction of mice caused by coronary artery occlusion. The invention provides the application of the traditional Chinese medicine in preparation of medicines for preventing or treating ischemic cardiomyopathy.
An initial triage level classification for a latest patient to arrive at an emergency department (ED) is received. Availability levels of resources needed to treat the latest patient are electronically collected, along with triage level classifications for all other patients currently in the ED. The initial triage level classification of the latest patient is adjusted upward or downward based on the availability levels of resources needed to treat the latest patient and based on the triage level classifications for the patients in the ED. The triage level classifications for all patients currently in the ED are summed up. If a sum of all triage level classifications exceeds a first predetermined threshold, other resources are reallocated in order to provide the resources needed to treat the latest patient to arrive at the ED. If the sum of all triage level classifications exceeds a second predetermined threshold, then a disaster plan is implemented.
OBJECTIVE: The aim of this study is to develop a nomogram model for predicting the occurrence of intramyocardial hemorrhage (IMH) in patients with Acute Myocardial Infarction (AMI) following Percutaneous Coronary Intervention (PCI). The model is constructed utilizing clinical data and the SYNTAX Score (SS), and its predictive value is thoroughly evaluated.
METHODS: A retrospective study was conducted, including 216 patients with AMI who underwent Cardiac Magnetic Resonance (CMR) within a week post-PCI. Clinical data were collected for all patients, and their SS were calculated based on coronary angiography results. Based on the presence or absence of IMH as indicated by CMR, patients were categorized into two groups: the IMH group (109 patients) and the non-IMH group (107 patients). The patients were randomly divided in a 7:3 ratio into a training set (151 patients) and a validation set (65 patients). A nomogram model was constructed using univariate and multivariate logistic regression analyses. The predictive capability of the model was assessed using Receiver Operating Characteristic (ROC) curve analysis, comparing the predictive value based on the area under the ROC curve (AUC).
RESULTS: In the training set, IMH post-PCI was observed in 78 AMI patients on CMR, while 73 did not show IMH. Variables with a significance level of P < 0.05 were screened using univariate logistic regression analysis. Twelve indicators were selected for multivariate logistic regression analysis: heart rate, diastolic blood pressure, ST segment elevation on electrocardiogram, culprit vessel, symptom onset to reperfusion time, C-reactive protein, aspartate aminotransferase, lactate dehydrogenase, creatine kinase, creatine kinase-MB, high-sensitivity troponin T (HS-TnT), and SYNTAX Score. Based on multivariate logistic regression results, two independent predictive factors were identified: HS-TnT (Odds Ratio [OR] = 1.61, 95% Confidence Interval [CI]: 1.21-2.25, P = 0.003) and SS (OR = 2.54, 95% CI: 1.42-4.90, P = 0.003). Consequently, a nomogram model was constructed based on these findings. The AUC of the nomogram model in the training set was 0.893 (95% CI: 0.840-0.946), and in the validation set, it was 0.910 (95% CI: 0.823-0.970). Good consistency and accuracy of the model were demonstrated by calibration and decision curve analysis.
CONCLUSION: The nomogram model, constructed utilizing HS-TnT and SS, demonstrates accurate predictive capability for the risk of IMH post-PCI in patients with AMI. This model offers significant guidance and theoretical support for the clinical diagnosis and treatment of these patients.